Newsfeeds - Spark Newswire

1 minute read

Uncategorized

Pliant Therapeutics Announces Positive DSMB Safety Review And Initiation of Enrollment Of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose In Primary Sclerosing Cholangitis

March 13, 8:04 AM

Bexotegrast, is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins being developed for the treatment of PSC and idiopathic pulmonary fibrosis (IPF). Bexotegrast has been

PLRX

1 minute read

RBC Capital Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $58

By Benzinga Newsdesk

March 10, 10:44 AM

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target from $60 to $58.

PLRX

1 minute read

JP Morgan Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $47

By Benzinga Newsdesk

March 10, 9:25 AM

JP Morgan analyst Eric Joseph maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $51 to $47.

PLRX

1 minute read

Pliant Therapeutics Q4 EPS $(0.72) Misses $(0.70) Estimate, Sales $1.97M Beat $1.43M Estimate

By Michael Horton

March 9, 5:15 PM

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.70) by 2.86 percent. This is a 5.88 percent decrease over losses of $(0.68) per share

PLRX

1 minute read

Novartis Takes Down $80M NASH Pact With Pliant Therapeutics

By Vandana Singh

February 24, 12:03 PM

Novartis AG (NYSE:NVS) has decided to terminate the Collaboration and License Agreement with Pliant Therapeutics, Inc.(NASDAQ:PLRX), announced in 2019. Novartis told…

NVS

1 minute read

Reported Late Tuesday, Pliant Therapeutics Announces Pricing Of Upsized $250M Public Offering Of 8,333,334 Shares Of Common Stock At A Price Of $30/Share

By Benzinga Newsdesk

January 25, 1:53 AM

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized

PLRX

1 minute read

Citigroup Maintains Buy on Pliant Therapeutics, Raises Price Target to $55

By Benzinga Newsdesk

January 24, 7:47 AM

Citigroup analyst David Lebowitz maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and raises the price target from $36 to $55.

PLRX

1 minute read

SVB Leerink Maintains Outperform on Pliant Therapeutics, Raises Price Target to $45

By Benzinga Newsdesk

January 24, 5:44 AM

SVB Leerink analyst Mike Kratky maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and raises the price target from $33 to $45.

PLRX

3 minute read

Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher

By Lisa Levin

January 23, 4:03 PM

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The S&P 500 also rose, gaining, 0.85% to 4,006.43.

ANPC